0.8825
price down icon2.08%   -0.0187
after-market 시간 외 거래: .90 0.0175 +1.98%
loading
전일 마감가:
$0.9012
열려 있는:
$0.9049
하루 거래량:
80,209
Relative Volume:
0.03
시가총액:
$1.74M
수익:
$644.60K
순이익/손실:
$-9.87M
주가수익비율:
-0.00105
EPS:
-837.9618
순현금흐름:
$-9.02M
1주 성능:
+5.31%
1개월 성능:
-4.12%
6개월 성능:
-79.71%
1년 성능:
-95.54%
1일 변동 폭
Value
$0.8825
$0.91
1주일 범위
Value
$0.81
$0.9502
52주 변동 폭
Value
$0.7846
$19.75

Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Company Profile

Name
명칭
Biodexa Pharmaceuticals Plc Adr
Name
전화
-
Name
주소
-
Name
직원
13
Name
트위터
Name
다음 수익 날짜
2024-06-13
Name
최신 SEC 제출 서류
Name
BDRX's Discussions on Twitter

BDRX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
BDRX
Biodexa Pharmaceuticals Plc Adr
0.8825 4.55M 644.60K -9.87M -9.02M -837.96
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.95 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.39 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.64 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
575.42 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.83 31.99B 3.81B -644.79M -669.77M -6.24

Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-02-08 개시 Ladenburg Thalmann Buy

Biodexa Pharmaceuticals Plc Adr 주식(BDRX)의 최신 뉴스

pulisher
Jul 15, 2025

Biodexa Pharmaceuticals Announces ADR Ratio Change Effective July 31, 2025 - TipRanks

Jul 15, 2025
pulisher
Jul 15, 2025

Biodexa Pharmaceuticals Announces Reverse ADR Split to Regain Nasdaq Compliance - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

Biodexa Pharmaceuticals PLC Announces ADR Ratio Change Effective July 31, 2025 - Nasdaq

Jul 15, 2025
pulisher
Jul 15, 2025

Biodexa Pharmaceuticals to implement 1:10 ADR ratio change - Investing.com

Jul 15, 2025
pulisher
Jul 15, 2025

Biodexa Pharmaceuticals PLC Announces ADR Ratio Change from 1:10 to 1:100,000. - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

MFS Extends Deadline for Liquidity Event for MFS Investment Grade Municipal Trust - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

ADR Ratio Change - GlobeNewswire

Jul 15, 2025
pulisher
Jul 15, 2025

Biodexa Plans Major ADR Restructuring: 1:10 Reverse Split to Meet Nasdaq Requirements - Stock Titan

Jul 15, 2025
pulisher
Jul 14, 2025

Biodexa files European clinical trial application for FAP treatment By Investing.com - Investing.com India

Jul 14, 2025
pulisher
Jul 14, 2025

Biodexa files European clinical trial application for FAP treatment - Investing.com

Jul 14, 2025
pulisher
Jul 14, 2025

Biodexa's $20M-Backed Phase 3 Trial for Rare Cancer Prevention Drug Expands to Europe - Stock Titan

Jul 14, 2025
pulisher
Jul 14, 2025

SMX (Security Matters) Plc (SMX) Stock: Navigating Drops and Gains - investchronicle.com

Jul 14, 2025
pulisher
Jul 09, 2025

Company’s Banking Stock: Dissecting a 60.04% Quarterly Revenue Decline Amid Growth - investchronicle.com

Jul 09, 2025
pulisher
Jun 27, 2025

Results of Annual General Meeting - GlobeNewswire

Jun 27, 2025
pulisher
Jun 25, 2025

Biodexa's $20M-Backed Phase 3 Trial for Rare Genetic Disease FAP Begins Patient Enrollment - Stock Titan

Jun 25, 2025
pulisher
Jun 23, 2025

Biodexa Unveils Phase 3 FAP Trial "Serenta": New Hope for Rare Disease Patients - Stock Titan

Jun 23, 2025
pulisher
Jun 18, 2025

Biodexa enrolls first patient in type 1 diabetes drug trial - Investing.com

Jun 18, 2025
pulisher
Jun 13, 2025

Biodexa Pharmaceuticals changes share nominal value By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 13, 2025

Biodexa Pharmaceuticals changes share nominal value - Investing.com

Jun 13, 2025
pulisher
Jun 11, 2025

Biodexa shareholders approve all resolutions at general meeting By Investing.com - Investing.com India

Jun 11, 2025
pulisher
Jun 11, 2025

Biodexa shareholders approve all resolutions at general meeting - Investing.com

Jun 11, 2025
pulisher
Jun 04, 2025

Phase 2 Trial Begins: Biodexa's Breakthrough Type 1 Diabetes Drug Shows Promise in Human Cells - Stock Titan

Jun 04, 2025
pulisher
May 22, 2025

Biodexa secures additional $3M for cancer drug trial By Investing.com - Investing.com India

May 22, 2025
pulisher
May 22, 2025

BDRXBiodexa Pharmaceuticals plc Latest Stock News & Market Updates - Stock Titan

May 22, 2025
pulisher
May 22, 2025

Biodexa secures additional $3M for cancer drug trial - Investing.com

May 22, 2025
pulisher
May 20, 2025

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here - sharewise

May 20, 2025
pulisher
May 20, 2025

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Nasdaq

May 20, 2025
pulisher
May 15, 2025

Biodexa Pharmaceuticals adjusts warrant exercise price - Investing.com

May 15, 2025
pulisher
May 15, 2025

Biodexa Pharmaceuticals adjusts warrant exercise price By Investing.com - Investing.com India

May 15, 2025
pulisher
May 12, 2025

Biodexa gains orphan drug status in EU for colon disease treatment - Investing.com

May 12, 2025
pulisher
May 12, 2025

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP - GlobeNewswire

May 12, 2025
pulisher
May 02, 2025

Result of General Meeting - GlobeNewswire

May 02, 2025
pulisher
Apr 24, 2025

What Makes Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) a New Buy Stock - MSN

Apr 24, 2025
pulisher
Apr 17, 2025

Biodexa Shareholders to Vote on Strategic Share Subdivision Plan: Key Meeting Details Revealed - Stock Titan

Apr 17, 2025
pulisher
Apr 11, 2025

Biodexa Annual Results Reveal Clinical-Stage Pipeline Expansion Strategy - Stock Titan

Apr 11, 2025
pulisher
Mar 19, 2025

Biodexa Pharmaceuticals advances FAP treatment trial By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Biodexa Pharmaceuticals advances FAP treatment trial - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter - BioSpace

Mar 19, 2025
pulisher
Mar 10, 2025

Biodexa gets FDA nod for Phase 3 eRapa study in FAP - Investing.com India

Mar 10, 2025
pulisher
Mar 07, 2025

Why Plus Therapeutics, Inc. (PSTV) Soared on Thursday - Yahoo Finance

Mar 07, 2025
pulisher
Mar 06, 2025

Biodexa selects Precision as CRO for eRapa Phase 3 study in Europe - Investing.com

Mar 06, 2025
pulisher
Feb 12, 2025

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status - Barchart

Feb 12, 2025
pulisher
Feb 11, 2025

Biodexa Pharmaceuticals Plc ADR [BDRX] Is Currently 31.94 above its 200 Period Moving Avg: What Does This Mean? - The DBT News

Feb 11, 2025
pulisher
Feb 10, 2025

why Teva- Pharmaceutical Industries Ltd. ADR [TEVA] is a Good Choice for Investors After New Price Target of $24.71 - The DBT News

Feb 10, 2025
pulisher
Feb 10, 2025

Palantir Technologies Inc [PLTR] Is Currently -0.39 below its 200 Period Moving Avg: What Does This Mean? - The DBT News

Feb 10, 2025
pulisher
Feb 10, 2025

Biodexa Pharmaceuticals Plc ADR (BDRX) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle

Feb 10, 2025
pulisher
Feb 10, 2025

Hesai Group ADR (HSAI) Shares Up Despite Recent Market Volatility - The News Heater

Feb 10, 2025
pulisher
Feb 10, 2025

Biodexa Pharmaceuticals Plc ADR (BDRX) vs. Its Peers: A Comparison - The News Heater

Feb 10, 2025
pulisher
Feb 10, 2025

Omega Therapeutics Inc (OMGA) Stock: A SWOT Analysis - The News Heater

Feb 10, 2025
pulisher
Feb 10, 2025

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis - GlobeNewswire

Feb 10, 2025
pulisher
Feb 10, 2025

AES Corp (AES) Shares Down Despite Recent Market Volatility - The News Heater

Feb 10, 2025

Biodexa Pharmaceuticals Plc Adr (BDRX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$22.87
price up icon 4.91%
$36.01
price down icon 0.25%
$103.44
price up icon 0.51%
$28.01
price up icon 5.54%
$114.60
price up icon 2.84%
biotechnology ONC
$294.83
price down icon 0.26%
자본화:     |  볼륨(24시간):